Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,659 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Luteolin, Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Completed No phase listed Observational

Oral Manifestations of Aplastic Anemia

NCT00006300
Conditions
Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

NCT00222807
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Schizophrenia
Interventions
Risperidone, Paliperidone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Irvine, California
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
salsalate
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Schizophrenia
Interventions
quetiapine fumarate vs risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
Conditions
Schizophrenia
Interventions
Paliperidone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Catonsville, Maryland
Conditions
Prodromal Schizophrenia, Psychotic Disorders
Interventions
risperidone, sertraline-primary
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Glen Oaks, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Completed No phase listed Observational Results available

Optimizing Cognitive Remediation

NCT04395157
Conditions
Schizophrenia, Stress Disorders, Post-Traumatic, Generalized Anxiety Disorder, Mood Disorders
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
Interventions
BTSCS, StSST
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
Social Skills Coach
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Needham, Massachusetts
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depressive Disorder
Interventions
CBTpro
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Morgan Hill, California • San Jose, California + 8 more
Conditions
Schizophrenia
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
Conditions
Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 19 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Cognitive Remediation Outcomes in Schizophrenia

NCT02105779
Conditions
Schizophrenia, Psychosis
Interventions
Targeted Cognitive Training, Social Cognitive Training
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Completed Not applicable Interventional Results available

Early Detection and Intervention for the Prevention of Psychosis

NCT00531518
Conditions
Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions
aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
Drug · Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 25 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more
Conditions
Schizophrenia
Interventions
talnetant, risperidone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
31
States / cities
Scottsdale, Arizona • Cerritos, California • Chula Vista, California + 27 more
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland